FindTrial
Sign In

Observation protocol for the efficacy of Edaravone Dexborneol in patients with acute ischemic stroke after alteplase therapy

Observation protocol for the efficacy of Edaravone Dexborneol in patients with acute ischemic stroke after alteplase therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086909
Enrollment
Unknown
Registered
2024-07-15
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

The group received a Edaravone Dexborneol concentrated solution for injection:NA
The group did not receive Edaravone Dexborneol concentrated solution for injection:NA

Sponsors

Department of Neurology of Shanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Ischemic stroke patients receiving intravenous thrombolysis with alteplase;To be treated with Edaravone Dexborneol for injection within 48h of onset.

Exclusion criteria

Exclusion criteria: Patients with contraindication of intravenous thrombolysis for Chinese Guidelines for Acute ischemic Stroke 2018;Intravenous thrombolysis for bridging the endovascular therapy;Patients with intracranial hemorrhage after intravenous thrombolysis.

Design outcomes

Primary

MeasureTime frame
modified Rankin scale;—

Secondary

MeasureTime frame
NIH Stroke Scale;—

Countries

China

Contacts

Public ContactFengyun Hu

Department of Neurology of Shanxi Provincial People's Hospital

fengyun71@163.com+86 138 3423 3638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026